Tetracyclines: A pleitropic family of compounds with promising therapeutic properties. Review of the literature

American Journal of Physiology - Cell Physiology

Volumn 299, Issue 3, 2010, Pages

  Griffin, Michael O ^a   Fricovsky, Eduardo ^b   Ceballos, Guillermo ^b,c   Villarreal, Francisco ^b  

^a Wheaton Franciscan Healthcare St Joseph   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Doxycycline; Minocycline; Protease inhibitors

Indexed keywords

4 DE DIMETYLAMINO TETRACYCLINE DERIVATIVE; CHLORTETRACYCLINE; DOXYCYCLINE; DOXYCYCLINE HYCLATE; INCYCLINIDE; MATRIX METALLOPROTEINASE; MINOCYCLINE; REACTIVE OXYGEN METABOLITE; SERINE PROTEINASE INHIBITOR; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ACNE; ACUTE DISEASE; ADULT RESPIRATORY DISTRESS SYNDROME; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANEURYSM; ANTHRAX; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHMA; ATROPHY; AUTISM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN TUMOR; CHLAMYDIASIS; CHOLERA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMMUNITY ACQUIRED PNEUMONIA; DIABETIC RETINOPATHY; DRUG ISOLATION; DRUG SALIVA LEVEL; DRUG STRUCTURE; DRUG UPTAKE; DRY EYE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROSING ALVEOLITIS; FRAGILE X SYNDROME; GINGIVITIS; HUMAN; HUNTINGTON CHOREA; KAPOSI SARCOMA; KIDNEY INJURY; LIPOPHILICITY; LYME DISEASE; LYMPHANGIOLEIOMYOMATOSIS; MEDICAL LITERATURE; METASTASIS; NEUROPROTECTION; NONHUMAN; OSTEOARTHRITIS; PARKINSON DISEASE; PERIODONTAL DISEASE; PERIODONTITIS; PLAGUE; PLEIOTROPY; PNEUMOTHORAX; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; PSYCHOSIS; REVIEW; RHEUMATOID ARTHRITIS; ROSACEA; SCHIZOPHRENIA; SCLEROSING CHOLANGITIS; SOLID TUMOR; SPINAL CORD INJURY; SYPHILIS; ULCER; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CLINICAL TRIALS AS TOPIC; HUMANS; TETRACYCLINES;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA; RICKETTSIACEAE;

EID: 77956562826     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00047.2010     Document Type: Review

References (103)

1. Ambrosio G, Becker LC, Hutchins GM, Weisman HF, Weisfeldt ML. Reduction in experimental infarct size by recombinant human superoxide dismutase: insights into the pathophysiology of reperfusion injury. Circulation 74: 1424-1433, 1986.
2. Baker PJ, Evans RT, Coburn RA, Genco RJ. Tetracycline and its derivatives strongly bind to and are released from the tooth surface in active form. J Periodontol 54: 580-585, 1983.
3. Barza M, Brown RB, Shanks C, Gamble C, Weinstein L. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs. Antimicrob Agents Chemother 8: 713-720, 1975.
4. Berthon G, Brion M, Lambs L. Metal ion-tetracycline interactions in biological fluids. 2. Potentiometric study of magnesium complexes with tetracycline, oxytetracycline, doxycycline, and minocycline, and discussion of their possible influence on the bioavailability of these antibiotics in blood plasma. J Inorg Biochem: 1-18, 1983. (Pubitemid 13020170)
5. Blackwood RK, English AR. Structure-activity relationships in the tetracycline series. Adv Appl Microbiol; 13237-266, 1970.
6. Brion M, Lambs L, Berthon G. Metal ion-tetracycline interactions in biological fluids. Part 5 Formation of zinc complexes with tetracycline and some of its derivatives and assessment of their biological significance. Agents Actions 17: 229-242, 1975.
7. Burns FR, Stack MS, Gray RD, Paterson CA. Inhibition of purified collagenase from alkali- burned rabbit corneas. Invest Ophthalmol Vis Sci 30: 1569-1575, 1989.
8. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med: 797-801, 2000.
9. Chen Z, Siu B, Ho YS, Vincent R, Chua CC, Hamdy RC, Chua BH. Overexpression of MnSOD protects against myocardial ischemia/reperfusion injury in transgenic mice. J Mol Cell Cardiol 30: 2281-2289, 1998.
10. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101: 1833-1839, 2000.
11. Colaizzi JL, Klink PR. pH-Partition behavior of tetracyclines. J Pharm Sci 58: 1184-1189, 1969.
12. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-ordeath switch. Nat Rev Cancer 2: 647-656, 2002. (Pubitemid 37328916)
13. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 89: 201-210, 2001.
14. Crout RJ, Lee HM, Schroeder K, Crout H, Ramamurthy NS, Wiener M, et al. The "cyclic" regimen of low-dose doxycycline for adult periodontitis: a preliminary study. J Periodontol 67: 506-514, 1996.
15. Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ. Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother 50: 3124-3131, 2006.
16. Danielsen CC, Wiggers H, Andersen HR. Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. J Mol Cell Cardiol 30: 1431-1442, 1998. (Pubitemid 28345043)
17. Desrochers PE, Mookhtiar K, Van Wart HE, Hasty KA, Weiss SJ. Proteolytic inactivation of alpha 1-proteinase inhibitor and alpha 1-antichymotrypsin by oxidatively activated human neutrophil metalloproteinases. J Biol Chem 267: 5005-5012, 1992.
18. Ding B, Price RL, Goldsmith EC, Borg TK, Yan X, Douglas PS, et al. Left ventricular hypertrophy in ascending aortic stenosis mice: anoikis and the progression to early failure. Circulation 101: 2854-2862, 2000.
19. d'Ortho MP, Will H, Atkinson S, Butler G, Messent A, Gavrilovic J, Smith B, Timpl R, Zardi L, Murphy G. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 250: 751-757, 1997.
20. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the M.PTP model of Parkinson's disease. Proc Natl Acad Sci USA 98: 14669-14674, 2001.
21. Duggar BM. Aureomycin: a product of the continuing search for new antibiotics. Ann NY Acad Sci 51: 177-181, 1948.
22. Esterly NB, Koransky JS, Furey NL, Trevisan M. Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy. Arch Dermatol 120: 1308-1313, 1984. (Pubitemid 14041779)
23. Etoh T, Joffs C, Deschamps AM, Davis J, Dowdy K, Hendrick J, Baicu S, Mukherjee R, Manhaini M, and Spinale FG. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol Heart Circ Physiol 281: H987-H994, 2001.
24. Fischer U, Jänicke RU, Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 10: 76-100, 2003. (Pubitemid 36511834)
25. Forloni G, Iussich S, Awan T, Colombo L, Angeretti N, Girola L, Bertani I, Poli G, Caramelli M, Grazia Bruzzone M, Farina L, Limido L, Rossi G, Giaccone G, Ironside JW, Bugiani O, Salmona M, Tagliavini. Tetracyclines affect prion infectivity. Proc Natl Acad Sci USA 99: 10849-10854, 2002.
26. Gabler WL, Tsukuda N. The influence of divalent cations and doxycycline on iodoacetamide-inhibitable leukocyte adherence. Res Commun Chem Pathol Pharmacol 74: 131-140, 1991.
27. Garcia RA, Go KV, Villarreal FJ. Effects of timed administration of doxycycline or methylprednisolone on post-myocardial infarction inflammation and left ventricular remodeling in the rat heart. Mol Cell Biochem 300: 159-169, 2007.
28. García RA, Pantazatos DP, Gessner CR, Go KV, Woods VL, Villarreal FJ. Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycycline investigated by deuterium exchange mass spectrometry. Mol Pharmacol 67: 1128-1136, 2005.
29. Goldman RA, Hasan T, Hall CC, Strycharz WA, Cooperman BS. Photoincorporation of tetracycline into Escherichia coli ribosomes. Identification of the major proteins photolabeled by native tetracycline and tetracycline photoproducts and implications for the inhibitory action of tetracycline on protein synthesis. Biochemistry 22: 359-368, 1983.
30. Golub LM, Evans RT, McNamara TF, Lee HM, Ramamurthy NS. A non-antimicrobial tetracycline inhibits gingival matrix metalloproteinases and bone loss in Porphyromonas gingivalis-induced periodontitis in rats. Ann NY Acad Sci 732: 96-111, 1994.
31. Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, Ramamurthy NS. Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J Periodontal Res 18: 516-526, 1983.
32. Golub LM, McNamara TF, D'Angelo G, Greenwald RA, Ramamurthy NS. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res 66: 1310-1314, 1987. (Pubitemid 17127109)
33. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 2: 297-321, 1991.
34. Golub LM, Sorsa T, Lee HM, Ciancio S, Sorbi D, Ramamurthy NS, Gruber B, Salo T, Konttinen YT. Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. J Clin Periodontol 22: 100-109, 1995.
35. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89: 5547-5551, 1992.
36. Greenwald RA, Golub LM, Ramamurthy NS, Chowdhury M, Moak SA, Sorsa T. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation. Bone 22: 33-38, 1998.
37. Grenier D, Plamondon P, Sorsa T, Lee HM, McNamara T, Ramamurthy NS, Golub LM, Teronen O, Mayrand D. Inhibition of proteolytic, serpinolytic, and progelatinase-b activation activities of periodontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives. J Periodontol 73: 79-85, 2002.
38. Guignabert C, Taysse L, Calvet J, Planus E, Delamanche S, Galiacy S, d'Ortho MP. Effect of doxycycline on sulfur mustard-induced respiratory lesions in guinea pigs. Am J Physiol Lung Cell Mol Physiol 289: L67-L74, 2005. (Pubitemid 40863556)
39. Hash JH, Wishnick M, Miller PA. On the mode of action of the tetracycline antibiotics in Staphylococcus aureus. J Biol Chem 239: 2070-2078, 1964.
40. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion - a target for cardioprotection. Cardiovasc Res 61: 372-385, 2004.
41. Hanemaaijer R, Sorsa T, Konttinen YT, Ding Y, Sutinen M, Visser H, van Hinsbergh VW, Helaakoski T, Kainulainen T, Rönkä H, Tschesche H, Salo T. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J Biol Chem 272: 31504-31509, 1997.
42. Hinrichs W, Kisker C, Düvel M, Müller A, Tovar K, Hillen W, et al. Structure of the Tet repressor-tetracycline complex and regulation of antibiotic resistance. Science 264: 418-420, 1994. (Pubitemid 24178904)
43. Hoeben D, Burvenich C, Heyneman R. Antibiotics commonly used to treat mastitis and respiratory burst of bovine polymorphonuclear leukocytes. J Dairy Sci 81: 403-410, 1998.
44. Holman BL. Radionuclide methods in the evaluation of myocardial ischemia and infarction. Circulation 53, Suppl: I112-I119, 1976.
45. Holman BL, Zweiman FG. Time course of 99mTc(Sn)-tetracycline uptake in experimental acute myocardial infarction. J Nucl Med 16: 1144-1146, 1975.
46. Jiang X, Wang X. Cytochrome C-mediated apoptosis. Annu Rev Biochem 73: 87-106, 2004.
47. Jolly SR, Kane WJ, Bailie MB, Abrams GD, Lucchesi BR. Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase. Circ Res 54: 277-285, 1984.
48. Jonat C, Chung FZ, Baragi VM. Transcriptional downregulation of stromelysin by tetracycline. J Cell Biochem 60: 341-347, 1996.
49. Jones D. Reactive oxygen species and rosacea. Cutis 74, Suppl 3: 17-20, 32-34, 2004.
50. Joshi NJ, Miller D. Doxycycline revisited. Arch Intern Med 157: 1421-1428, 1997.
51. Korting HC, Schöllman C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol 22: 187-194, 2009.
52. Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem 94: 819-827, 2005.
53. Lambs L, Brion M, Berthon G. Metal ion-tetracycline interactions in biological fluids. Part 3: Formation of mixed-metal ternary complexes of tetracycline, oxytetracycline, doxycycline and minocycline with calcium and magnesium, and their involvement in the bioavailability of these antibiotics in blood plasma. Agents Actions 14: 743-750, 1984. (Pubitemid 14087185)
54. León H, Baczkó I, Sawicki G, Light PE, Schulz R. Inhibition of matrix metalloproteinases prevents peroxynitrite-induced contractile dysfunction in the isolated cardiac myocyte. Br J Pharmacol 153: 676-683, 2008.
55. Levy SB, McMurry L. Detection of an inducible membrane protein associated with R-factor-mediated tetracycline resistance. Biochem Biophys Res Commun 56: 1060-1068, 1974.
56. McNamara TF, Golub LM, D'Angelo G, Ramamurthy NS. The synthesis and characterization of non-antimicrobial chemically-modified tetracycline (CMT) (Abstract). J Dent Res 65: IADR no. 515, 1986.
57. Michaelis J, Vissers MC, Winterbourn CC. Human neutrophil collagenase cleaves alpha 1-antitrypsin. Biochem J 270: 809-814, 1990.
58. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 274: 21491-21494, 1999.
59. Nagata S, Nagase H, Kawane K, Mukae N, Fukuyama H. Degradation of chromosomal DNA during apoptosis. Cell Death Differ 10: 108-116, 2003.
60. Näslund U, Häggmark S, Johansson G, Marklund SL, Reiz S, Oberg A. Superoxide dismutase and catalase reduce infarct size in a porcine myocardial occlusion-reperfusion model. J Mol Cell Cardiol 18: 1077-1084, 1986.
61. Nelson ML. Chemical and biological dynamics of tetracyclines. Adv Dent Res 12: 5-11, 1998.
62. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg 68: 1905-1912, 1999.
63. Pelle MT, Crawford GH, James WD. Rosacea II Therapy. J Am Acad Dermatol 51: 499-512, 2004.
64. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 9: 63-79, 2004. (Pubitemid 38202142)
65. Pruzanski W, Greenwald RA, Street IO, La-leberte F, Stefanski E, vadas P. Inhibition of enzymatic activity of phospholipase A2 by minocycline and doxycycline. Biochem Pharmacol 44: 1165-1170, 1992.
66. Ramamurthy NS, Vernillo AT, Greenwald RA, Lee HM, Sorsa T, Golub LM, Rifkin BR. Reactive oxygen species activate and tetracyclines inhibit rat osteoblast collagenase. J Bone Miner Res 8: 1247-1253, 1993.
67. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, Lee RT. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99: 3063-3070, 1999.
68. Romanic AM, Burns-Kurtis CL, Gout B, Berrebi-Bertrand I, Ohlstein EH. Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sci 68: 799-814, 2001. (Pubitemid 32168010)
69. Romero-Perez D, Fricovsky E, Yamasaki KG, Griffin M, Barraza- Hidalgo M, Dillmann W, Villarreal F. Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. J Am Coll Cardiol 52: 1086-1094, 2008.
70. Ryan ME, Usman A, Ramamurthy NS, Golub LM, Greenwald RA. Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. Curr Med Chem 8: 305-316, 2001.
71. Sabri A, Alcott SG, Elouardighi H, Pak E, Derian C, Andrade- Gordon P, Kinnally K, Steinberg SF. Neutrophil cathepsin G promotes detachment-induced cardiomyocyte apoptosis via a protease-activated receptor-independent mechanism. J Biol Chem 278: 23944-23954, 2003.
72. Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene 23: 2861-2874, 2004.
73. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 8: 1393-1401, 2001. (Pubitemid 32472597)
74. Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG, Szczesna-Cordary D, Schulz R. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 112: 544-552, 2005.
75. Scarabelli TM, Stephanou A, Pasini E, Gitti G, Townsend P, Lawrence K, Chen-Scarabelli C, Saravolatz L, Latchman D, Knight R, Gardin J. Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. J Am Coll Cardiol 43: 865-874, 2004.
76. Semenkov YuP, Makarov EM, Makhno VI, Kirillov SV. Kinetic aspects of tetracycline action on the acceptor (A) site of Escherichia coli ribosomes. FEBS Lett 144: 125-129, 1982.
77. Smith GN, Brandt KD, Mickler EA, Hasty KA. Inhibition of recombinant human neutrophil collagenase by doxycycline is pH dependent. J Rheumatol 24: 1769-1773, 1997.
78. Smith GN, Mickler EA, Hasty KA, Brandt KD. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. Arthritis Rheum 42: 1140-1146, 1999.
79. Sorsa T, Ding Y, Salo T, Lauhio A, Teronen O, Ingman T, Ohtani H, Andoh N, Takeha S, Konttinen YT. Effects of tetracyclines on neutrophil, gingival, and salivary collagenases. A functional and western-blot assessment with special reference to their cellular sources in periodontal diseases. Ann NY Acad Sci 732: 112-131, 1994.
80. Sorsa T, Konttinen YT, Lindy O, Suomalainen K, Ingman T, Saari H, Halinen S, Lee HM, Golub LM, Hall J. Doxycycline protects serum alpha-1-antitrypsin from human neutrophil collagenase. Agents Actions Suppl 39: 225-229, 1993.
81. Sorsa T, Lindy O, Konttinen YT, Suomalainen K, Ingman T, Saari H, Halinen S, Lee HM, Golub LM, Hall J. Doxycycline in the protection of serum alpha-1-antitrypsin from human neutrophil collagenase, and gelatinase. Antimicrob Agents Chemother Mar 37: 592-594, 1993.
82. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90: 520-530, 2002.
83. Steinberg J, Halter J, Schiller H, Gatto L, Carney D, Lee H, Golub L, Nieman G. Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. Shock 24: 348-356, 2005.
84. Sun C, Wang Q, Brubaker JD, Wright PM, Lerner CD, Noson K, et al. A robust platform for the synthesis of new tetracycline antibiotics. J Am Chem Soc 130: 17913-17927, 2008.
85. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397: 441-446, 1999.
86. Takahashi M, Altschmied L, Hillen W. Kinetic and equilibrium characterization of the Tet repressor-tetracycline complex by fluorescence measurements. Evidence for divalent metal ion requirement and energy transfer. J Mol Biol 187: 341-348, 1986. (Pubitemid 16083776)
87. Thong YH, Ferrante A. Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues. Clin Exp Immunol 35: 443-446, 1979.
88. Thorburn A. Death receptor-induced cell killing. Cell Signal 16: 139-144, 2004.
89. Tritton TR. Ribosome-tetracycline interactions. Biochemistry 16: 4133-4138, 1977.
90. Villarreal F, Omens J, Dillmann W, Risteli J, Nguyen J, Covell J. Early degradation and serum appearance of type I collagen fragments after myocardial infarction. J Mol Cell Cardiol 36: 597-601, 2004.
91. Walters JD. Characterization of minocycline transport by human neutrophils. J Periodontol 7: 1964-1968, 2006.
92. Wang J, Wei Q, Wang C, Hill WD, Hess DC, Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem 279: 19948-19954, 2004.
93. Wang P, Chen H, Qin H, Sankarapandi S, Becher MW, Wong PC, Zweier JL. Overexpression of human copper, zinc-superoxide dismutase (SOD1) prevents postischemic injury. Proc Natl Acad Sci USA 95: 4556-4560, 1998. (Pubitemid 28207951)
94. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JRB, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106: 1543-1549, 2002.
95. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, Friedlander RM. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 100: 10483-10487, 2003.
96. Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin: involvement of protein kinase C. Arch Dermatol 130: 748-752, 1994.
97. Yamaguchi A, Udagawa T, Sawai T. Transport of divalent cations with tetracycline as mediated by the transposon Tn10-encoded tetracycline resistance protein. J Biol Chem 265: 4809-4813, 1990. (Pubitemid 20117111)
98. Yang Q, Nakkula RJ, Walters JD. Accumulation of ciprofloxacin and minocycline by cultured human gingival fibroblasts. J Dent Res 81: 836-840, 2002.
99. Yoshida T, Watanabe M, Engelman DT, Engelman RM, Schley JA, Maulik N, Ho YS, Oberley TD, Das DK. Transgenic mice overexpressing glutathione peroxidase are resistant to myocardial ischemia reperfusion injury. J Mol Cell Cardiol 28: 1759-1767, 1996.
100. Yu LP, Smith GN, Hasty KA, Brandt KD. Doxycycline inhibits type XI collagenolytic activity of extracts from human osteoarthritic cartilage and of gelatinase. J Rheumatol 18: 1450-1452, 1991.
101. Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 95: 15769-15774, 1998.
102. Zink MC, Uhrlaub J, DeWitt J, Voelker T, Bullock B, Mankowski J, Tarwater P, Clements J, Barber S. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 293: 2003-2011, 2005.
103. Zhu S, Stavrovskaya IG, Drozda M, Kim BYS, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417: 74-78, 2002.